Celine Dubath
Overview
Explore the profile of Celine Dubath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dubath C, Gholam-Rezaee M, Sjaarda J, Levier A, Saigi-Morgui N, Delacretaz A, et al.
Transl Psychiatry
. 2021 Oct;
11(1):512.
PMID: 34620835
No abstract available.
12.
Dubath C, Piras M, Gholam M, Laaboub N, Grosu C, Sentissi O, et al.
Pharmacopsychiatry
. 2021 Aug;
54(6):279-286.
PMID: 34388836
Introduction: The atypical antipsychotic quetiapine is known to induce weight gain and other metabolic complications. The underlying mechanisms are multifactorial and poorly understood with almost no information on the effect...
13.
Lenski M, Sidibe J, Gholam M, Hennart B, Dubath C, Augsburger M, et al.
Clin Transl Sci
. 2021 Aug;
14(6):2544-2555.
PMID: 34387942
Psychotropic drugs can induce strong metabolic adverse effects, potentially increasing morbidity and/or mortality of patients. Metabolomic profiling, by studying the levels of numerous metabolic intermediates and products in the blood,...
14.
Dubath C, Gholam-Rezaee M, Sjaarda J, Levier A, Saigi-Morgui N, Delacretaz A, et al.
Transl Psychiatry
. 2021 Jul;
11(1):360.
PMID: 34226496
Weight gain and metabolic complications are major adverse effects of many psychotropic drugs. We aimed to understand how socio-economic status (SES), defined as the Swiss socio-economic position (SSEP), is associated...
15.
Delacretaz A, Glatard A, Dubath C, Gholam M, Gamma F, von Gunten A, et al.
Basic Clin Pharmacol Toxicol
. 2021 Mar;
129(1):26-35.
PMID: 33733594
Few studies have evaluated the influence of valproate on the deterioration of the lipid profile in psychiatric patients. This observational study aimed to compare the evolution of metabolic parameters in...
16.
Alameda L, Levier A, Gholam-Rezaee M, Golay P, Vandenberghe F, Delacretaz A, et al.
PLoS One
. 2020 Dec;
15(12):e0242569.
PMID: 33270646
Background: It has been suggested that exposure to Childhood Trauma [CT] may play a role in the risk of obesity in Early Psychosis [EP] patients; however, whether this is independently...
17.
Dubath C, Delacretaz A, Glatard A, Vollenweider P, Preisig M, Richard-Lepouriel H, et al.
J Clin Psychiatry
. 2020 Apr;
81(3).
PMID: 32237298
Background: Psychiatric patients are known to be at high risk of developing cardiovascular diseases (CVDs), leading to an increased mortality rate. Objective: To assess the CVD risk (presence of metabolic...
18.
Delacretaz A, Glatard A, Dubath C, Gholam-Rezaee M, Sanchez-Mut J, Graff J, et al.
Clin Epigenetics
. 2019 Dec;
11(1):198.
PMID: 31878957
Background: Metabolic side effects induced by psychotropic drugs represent a major health issue in psychiatry. CREB-regulated transcription coactivator 1 (CRTC1) gene plays a major role in the regulation of energy...
19.
Glatard A, Guidi M, Delacretaz A, Dubath C, Grosu C, Laaboub N, et al.
Clin Pharmacokinet
. 2019 Sep;
59(3):371-382.
PMID: 31552612
Background: Amisulpride is an antipsychotic used in a wide range of doses. One of the major adverse events of amisulpride is hyperprolactinemia, and the drug might also induce body weight...
20.
Delacretaz A, Vandenberghe F, Glatard A, Dubath C, Levier A, Gholam-Rezaee M, et al.
J Clin Psychiatry
. 2019 Apr;
80(3).
PMID: 30997960
Objective: Lipid disturbances following treatment with second-generation antipsychotics (SGAs) represent a major health concern. A previous study determined that early changes of plasma lipid levels ≥ 5% during the first...